Mark L. Tykocinski
Presidente presso Thomas Jefferson University
Posizioni attive di Mark L. Tykocinski
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Thomas Jefferson University | Presidente | - | - |
Storia della carriera di Mark L. Tykocinski
Precedenti posizioni note di Mark L. Tykocinski
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
American Society for Investigative Pathology
 American Society for Investigative Pathology BiotechnologyHealth Technology The American Society for Investigative Pathology operates as a biotechnology company. | Presidente | - | - |
| University of Pennsylvania | Corporate Officer/Principal | - | - |
| Sidney Kimmel Medical College | Corporate Officer/Principal | - | - |
| Thomas Jefferson University | Corporate Officer/Principal | - | - |
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Direttore Tecnico/Scientifico/R&S | 15/10/2009 | - |
| Fondatore | 01/01/2005 | - |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Israele | 2 |
Posizioni
| Corporate Officer/Principal | 3 |
| President | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Settori
| Consumer Services | 4 |
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
American Society for Investigative Pathology
American Society for Investigative Pathology BiotechnologyHealth Technology The American Society for Investigative Pathology operates as a biotechnology company. | Health Technology |
- Borsa valori
- Insiders
- Mark L. Tykocinski
- Esperienza
